An interventional study of Humanistic Continuing Care via WeChat and Usual Care (No Structured WeChat Program) in Papillary Thyroid Carcinoma, sponsored by Ming-an Yu. Recruiting at 1 site in China. Open to participants aged 16 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-07-14.
Sponsored by Ming-an Yu · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Thyroid Cancer, Papillary with a site in China — 24 open to participants now, 25 under way, 1 of them phase 3. Thyroid Cancer, Papillary · China.
Among the 40 studies in Thyroid Cancer, Papillary with a site in China, this one is the 14th largest by planned enrollment of the 21 interventional ones that give a count, is one of 5 that started in 2025, is one of 14 with no phase, reaches primary completion later than 12 of the 24 other live ones, and was the 36th registered.
186 studies on the registry are indexed under Thyroid Cancer, Papillary; 50 are open to participants now.
Browse Thyroid Cancer, Papillary studies →24 of the 40 studies in Thyroid Cancer, Papillary with a site in China are open now. Recruiting first, the newest first:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Second Affiliated Hospital of Xi'an Jiaotong University · Sites in China
Ages 16–80
Shanghai 6th People's Hospital · Sites in China
Chinese PLA General Hospital · Sites in China
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 31 Thyroid Cancer, Papillary studies recruiting now, 18 (58%) set no upper age limit and 8 (26%) stop at 75 or younger; 13 take children under 18; 3 take healthy volunteers.
This study: 16 Years to 60 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 3 · Phase 3 1 · Phase 4 2
First in 2015; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 108 is above the median of 41 across 114 interventional studies indexed under Thyroid Cancer, Papillary.
Median enrollment 170 across the 21 interventional studies, 541 across the 19 observational. Of the 11 that completed or were terminated, 2 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 40 have an industry lead sponsor. The 10 most frequent:
Ming-an Yu is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Ming-an Yu has 2 studies filed under Thyroid Cancer, Papillary — fewer than ten, so there is no comparison to draw.
5 of the studies in Thyroid Cancer, Papillary with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07357571Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityPreoperative Prediction of Lymph Node Metastasis in T1N0M0 Papillary Thyroid Carcinoma by Using Contrast-enhanced Ultrasound | 2026-12-31 |
| NCT06316895Chinese PLA General HospitalThe Clinical Outcomes and Prediction of Thermal Ablation for Low-risk Papillary Thyroid Carcinoma | 2027-04-01 |
| NCT06804863West China HospitalRegret Emotion After Thyroidectomy in Low-Risk Papillary Thyroid Cancer | 2027-05-01 |
| NCT06610604Ming-an YuHealth-Related Quality of Life and Emotions in Patients with Thyroid Nodules | 2027-06 |
| NCT02650401Hoffmann-La RocheStudy Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options | 2027-06-30 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Thyroid Cancer, Papillary with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to test whether human-centered nursing care lowers emotional distress and improves quality of life for people who are awake during thyroid thermal ablation. The procedure uses local anesthesia, so participants remain awake and may feel tense. Human-centered care focuses on emotional support, clear communication, comfort, and follow-up, and it may improve the experience and recovery for patients.
The main questions are:
Does human-centered nursing care reduce emotional distress levels in patients undergoing thyroid thermal ablation?
Does human-centered nursing care improve patient quality of life after thyroid thermal ablation?
If there is a comparison group: Researchers will compare human-centered nursing care to usual nursing care to see if human-centered care leads to lower emotional distress and higher quality of life.
Participants will:
Receive either human-centered nursing care or usual nursing care.
Complete questionnaires before, during, and after the procedure to measure emotional distress, quality of life, pain, and satisfaction with care.
Have their vital signs and quality of life tracked during and after the procedure.
Have their adherence to care plans and any complications monitored.
The main outcomes are emotional distress levels and quality of life. Other outcomes include pain and vital signs during the procedure, satisfaction with care, and complication rates. Results may guide better care for people undergoing small, minimally invasive treatments while awake.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Owns a smartphone and can use WeChat
Exclusion Criteria:
Behavioral: Humanistic Continuing Care via WeChat
Procedure: Usual Care (No Structured WeChat Program)
Description: Structured, humanistic peri-operative nursing program delivered through WeChat in addition to routine care. Components: pre-procedure needs assessment and expectation setting; brief coping skills coaching (e.g., paced breathing); intra-procedure step-by-step explanations, reassurance, and comfort measures; post-procedure education, recovery guidance, and psychosocial support; symptom monitoring with red-flag escalation; medication/wound-care and appointment reminders; on-demand messaging during service hours; optional caregiver engagement. Delivery \& Schedule: Nurse-led. One pre-procedure session; intra-procedure support on the day of ablation; post-procedure WeChat check-ins at least weekly plus on-demand messaging for 12 weeks. Fidelity tracked via standardized checklists. Arm(s): Experimental - Humanistic Continuing Care via WeChat.
Participants receive standard peri-operative nursing and institutional discharge materials, including routine pre-procedure counseling, standard intra-procedure monitoring, printed/posted instructions for home care, and follow-up per usual practice (e.g., clinic visit or routine phone call). They may contact the clinic using standard channels as needed, but there is no scheduled, structured WeChat outreach or humanistic continuing-care protocol.
Change in emotion distress from baseline to post-procedure (HADS)
Time frame: From enrollment to the end of treatment at 3 months
Change in the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 scores from baseline to 3 months
Time frame: From enrollment to the end of treatment at 3 months
Change in Thyroid Cancer-Specific Quality of Life Questionnaire scores from baseline to 3 months
Time frame: From enrollment to 3 months after end of treatment
Intraoperative pain intensity (Visual Analog Scale)
Pain intensity during the procedure will be assessed using a Visual Analog Scale (VAS; 0-100 mm, where 0 indicates no pain and 10 indicates the worst imaginable pain). A single VAS score will be recorded during the intraoperative period.
Time frame: Intraoperative period (during the procedure)
Patient satisfaction with nursing care (Newcastle Satisfaction with Nursing Scale, NSNS)
Time frame: Postoperative Day 1
Plan to share: Undecided — Undecided at this time; a final decision about IPD sharing will be made after publication in consultation with the institution's data governance and ethics committees.
No publications or documents are linked to this record.
Ran from Dec 2025 to primary completion in Jun 2026, 6 months.
Of 26 interventional studies with no phase under Thyroid Cancer, Papillary, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 71. This study's 6 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.